NesiritideB-type natriuretic peptide analogue
Nesiritide reproduces B-type natriuretic peptide, a hormone involved in vascular and fluid regulation. Clinical trials show why an attractive mechanism must still be tested against outcomes that matter to patients.
What is Nesiritide?
Nesiritide is a recombinant form of B-type natriuretic peptide developed for acute heart failure. Its effects on circulation have to be distinguished from longer-term outcomes such as survival or readmission. 1
How it works
It promotes vasodilation, changing the pressure and workload within the circulation. A favourable haemodynamic response does not by itself prove a clinical outcome benefit.
Effects studied
Death or heart-failure readmission
ASCEND-HF did not show a significant benefit for the combined endpoint of death or heart-failure rehospitalisation.
Evidence: Large randomised acute heart-failure trial. 1
What does the evidence show?
Large acute-heart-failure randomised trial
A hormone released under cardiac stress
The heart produces natriuretic peptides in response to stretch and pressure. Nesiritide uses the action of BNP to affect vessel tone and fluid handling. In acute heart failure, those effects suggested a possible way to relieve congestion and breathlessness.
What the large trial asked
ASCEND-HF studied nesiritide added to standard care in people hospitalised with acute heart failure. The retained paper reports no significant reduction in the combined outcome of death or heart-failure rehospitalisation. This is a more clinically direct test than observing a change in filling pressure alone. 1
Symptoms and longer-term outcomes are separate
Relieving breathlessness matters in its own right, but does not establish that a medicine prevents another hospital stay or extends life. Interpreting symptom relief requires knowing how it was measured and how large the difference was. Saying the drug “improves heart health” leaves these separate outcomes unclear.
The blood-pressure trade-off
Vasodilation can lower blood pressure too far, and hypotension was an important concern in the clinical discussion. Kidney function and the person’s overall circulation also matter. Although the natural hormone offered a rationale for treatment, the trials did not confirm every expected clinical benefit.
Safety & status
Hypotension is an important concern, and kidney function requires attention in the acute heart-failure setting. Blood-pressure changes must be interpreted alongside the patient’s overall circulation. 1
Country and product status
Product indications and availability vary by country; current EU and Swiss status has not been independently checked for this draft.
Frequently asked questions
Does improving circulation guarantee better survival?
No. ASCEND-HF illustrates why physiological effects and clinical outcomes must be measured separately. 1
Is this a general circulation supplement?
No. It is a recombinant peptide medicine studied in acute heart failure, not a nutritional product.
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Retained paper reference Archive research lead · Retained archive reference; not independently checked for this draft
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.